These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2963936)

  • 1. Elimination of immune suppressor mechanisms in humans by oxazaphosphorines.
    Berd D; Mastrangelo MJ
    Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):569-77. PubMed ID: 2963936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide.
    Berd D; Maguire HC; Mastrangelo MJ
    Cancer Res; 1984 Nov; 44(11):5439-43. PubMed ID: 6488195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset.
    Berd D; Mastrangelo MJ
    Cancer Res; 1987 Jun; 47(12):3317-21. PubMed ID: 2953413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer.
    Berd D; Maguire HC; Mastrangelo MJ
    Cancer Res; 1984 Mar; 44(3):1275-80. PubMed ID: 6229330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma.
    Livingston PO; Cunningham-Rundles S; Marfleet G; Gnecco C; Wong GY; Schiffman G; Enker WE; Hoffman MK
    J Biol Response Mod; 1987 Aug; 6(4):392-403. PubMed ID: 2957470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fractional cyclophosphamide dosage on sheep red blood cell-delayed-type hypersensitivity response in mice.
    Rondinone SN; Giovanniello OA; Barrios HA; Nota NR
    J Immunol; 1983 Apr; 130(4):1600-3. PubMed ID: 6220061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune modulating effects of low doses of cyclophosphamide and keyhole limpet hemocyanin on peripheral blood immune parameters in patients with metastatic renal cell carcinoma.
    Kleinknecht S; Bichler KH; Strohmaier WL
    Urol Int; 1992; 48(1):1-8. PubMed ID: 1598724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of the relation between suppressor and effector mechanisms in contact sensitivity in the guinea-pig.
    Parker D; Turk JL
    Immunology; 1982 Sep; 47(1):61-6. PubMed ID: 6214499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide pretreatment induces eosinophilia to nonparasite antigens.
    Vadas MA
    J Immunol; 1981 Nov; 127(5):2083-6. PubMed ID: 7299123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of the delayed-type hypersensitivity reaction by oxazaphosphorines.
    Turk JL
    Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):605-10. PubMed ID: 3325716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulation by corynebacterium parvum in two strains of guinea-pigs and the effect of cyclophosphamide.
    Gauthier-Rahman S
    Immunology; 1981 Jan; 42(1):99-109. PubMed ID: 7461727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of cell-mediated immunity in cryptococcosis. III. Characterization of second-order T suppressor cells (Ts2).
    Murphy JW; Mosley RL
    J Immunol; 1985 Jan; 134(1):577-84. PubMed ID: 3155471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of delayed hypersensitivity to tuberculin by antigenic competition. A positive immunoregulatory mechanism sensitive to cyclophosphamide.
    Dwyer JM; Parker D; Turk JL
    Immunology; 1981 Apr; 42(4):549-59. PubMed ID: 6453829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local administration of cytostatic drug 4-hydroperoxy-cyclophosphamide (4-HPCY) facilitates cell-mediated immune reactions.
    Boerrigter GH; Scheper RJ
    Clin Exp Immunol; 1984 Oct; 58(1):161-6. PubMed ID: 6478648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunoaugmenting effects of cancer chemotherapeutic agents.
    Mastrangelo MJ; Berd D; Maguire H
    Semin Oncol; 1986 Jun; 13(2):186-94. PubMed ID: 2940686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cyclophosphamide on the immune response of BALB/c mice bearing an immunoglobulin M plasmacytoma (TEPC-183).
    Havas HF; Schiffman G
    Cancer Res; 1981 Mar; 41(3):801-7. PubMed ID: 7459867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed-type hypersensitivity to sheep red blood cells in selected lines of mice with high or low antibody responses.
    Lagrange PH; Michel JC; Hurtrel B; Thickstun PM
    Ann Immunol (Paris); 1980; 131C(3):257-77. PubMed ID: 7406440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of T suppressor cell function by local administration of an active cyclophosphamide derivative at the sensitization site.
    Limpens J; Scheper RJ
    Clin Exp Immunol; 1991 Jun; 84(3):383-8. PubMed ID: 1828396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
    Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
    J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxazaphosphorine effects in L 5222 rat leukemia.
    Pohl J; Reissmann T; Voegeli R
    Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.